stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Revenue growth
Prestige Consumer Healthcare Inc.'s revenue growth over the twelve months to 30 September 2026 was 5.10%, up 9.4 percentage points from fiscal 2026 (−4.31%). Over the past ten years it has ranged from −6.28% (fiscal 2019) to 19.6% (fiscal 2015); the current reading is higher than 17% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 5.22% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | −4.31% | (5.41) |
| FY2025 | 1.10% | 1.31 |
| FY2024 | −0.21% | (3.97) |
| FY2023 | 3.76% | (11.45) |
| FY2022 | 15.2% | 17.25 |
| FY2021 | −2.04% | (0.73) |
| FY2020 | −1.31% | 4.97 |
| FY2019 | −6.28% | (24.32) |
| FY2018 | 18.0% | 8.64 |
| FY2017 | 9.40% | (3.42) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 22.7% | 16.21 |
| Jun 2026 | 6.48% | 11.51 |
| Mar 2026 | −5.03% | (2.66) |
| Dec 2025 | −2.37% | 1.04 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ALVO Alvotech compare | 364.3% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 245.2% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 60.3% |
| XERS Xeris Biopharma Holdings, Inc. compare | 38.4% |
| PBH Prestige Consumer Healthcare Inc. | 5.10% |
| PRGO Perrigo Company plc compare | −4.47% |
| TRLV Trulieve Cannabis Corp. compare | −9.09% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −77.1% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement